Emalex Biosciences
Jenny Swalec serves as Vice President of Regulatory Affairs and Quality Assurance at Emalex Biosciences. She is responsible for regulatory submissions and interactions with global health authorities.
Ms. Swalec has over 25 years of regulatory experience. Previously, she was Vice President of Regulatory Affairs at Castle Creek Pharmaceuticals, a Paragon portfolio company. Ms. Swalec served in the same role at Marathon Pharmaceuticals and as Senior Director of Global Regulatory Affairs at Lundbeck. She has played a pivotal role in multiple new drug applications in the U.S. that received first cycle approvals, as well as numerous global clinical trial applications. She began her career as Manager of Regulatory Affairs at Parke Davis. Ms. Swalec earned a bachelor’s degree in biology and chemistry from Eastern Michigan University.
This person is not in any offices
Emalex Biosciences
Emalex Biosciences, LLC is a biopharmaceutical company dedicated to the development of new treatments for rare and orphan neurological conditions. Ecopipam, its first development candidate, is a novel compound that has been studied as a potential treatment for many central nervous system (CNS) disorders, including pediatric Tourette Syndrome.